UNIVERSITY OF WASHINGTON
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1861-01-01
- Employees
- 10K
- Market Cap
- -
Waking Hypnosis in the Treatment of MS-related Fatigue
Not Applicable
Completed
- Conditions
- Multiple Sclerosis
- Interventions
- Behavioral: Traditional HypnosisBehavioral: Active-Alert Hypnosis
- First Posted Date
- 2020-06-12
- Last Posted Date
- 2021-05-03
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 32
- Registration Number
- NCT04429789
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
Streamlining the Efficiency of PrEP Implementation
Not Applicable
Completed
- Conditions
- HIV PreventionImplementationHIV Preexposure Prophylaxis
- Interventions
- Other: Direct-to-pharmacy oral PrEP refill visits
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 746
- Registration Number
- NCT04424524
- Locations
- 🇰🇪
Partners in Health Research and Development, Thika, Kenya
Flicker App for Minimal Hepatic Encephalopathy
- Conditions
- Hepatic Encephalopathy
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 75
- Registration Number
- NCT04415294
- Locations
- 🇺🇸
University of Washington Medical Center, Seattle, Washington, United States
VZV-specific Tissue Resident Memory T-cells After Shingrix Vaccination
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 50
- Registration Number
- NCT04403139
- Locations
- 🇺🇸
University of Washington Virology Research Clinic, Seattle, Washington, United States
Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 2
Recruiting
- Conditions
- Recurrent Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma
- Interventions
- Drug: CarboplatinBiological: PembrolizumabProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Biospecimen Collection
- First Posted Date
- 2020-05-13
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 22
- Registration Number
- NCT04387227
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer
Phase 2
Active, not recruiting
- Conditions
- Stage IIIA Bladder Cancer AJCC v8Muscle Invasive Bladder CarcinomaStage II Bladder Cancer AJCC v8
- Interventions
- Drug: CisplatinDrug: DoxorubicinDrug: MethotrexateBiological: PegfilgrastimBiological: PembrolizumabProcedure: Radical CystectomyDrug: Vinblastine Sulfate
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 17
- Registration Number
- NCT04383743
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Families Together: Intervention for Reunified Families
Not Applicable
Active, not recruiting
- Conditions
- Child NeglectChild Abuse
- Interventions
- Behavioral: Promoting First Relationships ®Other: Resource & Referral
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 240
- Registration Number
- NCT04382677
- Locations
- 🇺🇸
University of Washington, Child, Family, and Population Health Nursing, Seattle, Washington, United States
The Flipped Classroom Approach in Ophthalmology Residency
Completed
- Conditions
- Educational Problems
- Interventions
- Other: Flipped Classroom Approach
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2020-05-11
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 110
- Registration Number
- NCT04381676
- Locations
- 🇺🇸
Department of Ophthalmology - University of Washington, Seattle, Washington, United States
Effects of Pregnancy-associated Hormones on THC Metabolism in Women
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 12
- Registration Number
- NCT04374773
- Locations
- 🇺🇸
Nina Isoherranen, Seattle, Washington, United States
ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy
Phase 2
Terminated
- Conditions
- Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Locally Advanced Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8
- Interventions
- Drug: CisplatinBiological: DurvalumabDrug: EtoposideRadiation: Hypofractionated Radiation TherapyDrug: Pemetrexed
- First Posted Date
- 2020-05-04
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 1
- Registration Number
- NCT04372927
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
© Copyright 2025. All Rights Reserved by MedPath